Retatrutide Phase 3 Data: What Triple-Agonist Results Mean for GLP-1 Research

Retatrutide (LY3437943) is a novel triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Developed by Eli Lilly, it engages all three pathways in a single molecule, distinguishing it from dual agonists like Tirzepatide.

Phase 2 Trial Outcomes: The Foundation

The Phase 2 trial (NCT04881760), published in The New England Journal of Medicine in June 2023, enrolled 338 adults with obesity, or overweight plus a weight-related condition. At 48 weeks, participants in the highest-dose cohort achieved a mean body-weight reduction of 24.2%, and 83% of that cohort lost 15% or more of their body weight ^[1].

This level of weight reduction exceeded published results for both Semaglutide (14.9% at 68 weeks in the STEP 1 trial ^[2]) and Tirzepatide (up to 20.9% at 72 weeks in the SURMOUNT-1 trial ^[3]), placing Retatrutide among the most potent body-weight reduction peptides in clinical development, although these were separate trials rather than head-to-head comparisons.

The Glucagon Component: A Differentiating Factor

What separates Retatrutide from existing GLP-1 agonists is its activation of the glucagon receptor. Glucagon stimulates hepatic lipid oxidation and increases energy expenditure, a mechanism absent from GLP-1-only or GIP/GLP-1 dual agonists. In Lilly's discovery work in obese mice, glucagon receptor activity added an increase in energy expenditure to the reduced food intake driven by Retatrutide's GIP and GLP-1 receptor activity ^[4].

Researchers have hypothesised that the glucagon component may also confer hepatoprotective effects. In a substudy of 98 Phase 2 participants with metabolic dysfunction-associated steatotic liver disease, liver fat fell by a mean of 82.4% relative to baseline at 24 weeks in the highest-dose group, and 86% of that group reached normal liver fat levels ^[5].

Phase 3 Trial Design and Endpoints

The TRIUMPH programme encompasses multiple Phase 3 studies evaluating Retatrutide across different populations:

• TRIUMPH-1: Adults with obesity (BMI 30+) or overweight (BMI 27+) with weight-related comorbidities and without diabetes, including groups with knee osteoarthritis or obstructive sleep apnoea
• TRIUMPH-2: Adults with type 2 diabetes and obesity or overweight
• TRIUMPH-3: Adults with severe obesity (BMI 35+) and established cardiovascular disease
• TRIUMPH-4: Adults with obesity or overweight and knee osteoarthritis

The primary endpoint in each is percentage change in body weight from baseline, measured at 80 weeks (68 weeks in TRIUMPH-4), with knee pain and sleep apnoea measures as additional primary endpoints in the relevant groups. Secondary endpoints cover glycaemic measures, blood pressure, lipids and other cardiovascular risk markers.

Preliminary Phase 3 Findings

Phase 3 results began to arrive in December 2025, when Eli Lilly announced topline TRIUMPH-4 results, and full results from several trials were published in 2026. They have confirmed and extended the Phase 2 findings. Key observations include:

• In TRIUMPH-1 (2,339 adults with obesity and without diabetes), mean body-weight reduction was 25.0% at 80 weeks with the highest dose, versus 3.9% with placebo ^[6]
• In TRIUMPH-2 (adults with obesity and type 2 diabetes), the highest dose produced a mean reduction of 18.8% at 80 weeks, versus 5.1% with placebo ^[7]
• In TRANSCEND-T2D-1 (adults with type 2 diabetes), HbA1c fell by 1.69 to 1.94 percentage points across doses at 40 weeks, versus 0.81 with placebo ^[8]
• The most common adverse events were gastrointestinal and mostly mild to moderate, subsiding over time in TRANSCEND-T2D-1 ^[8]; dysaesthesia and hypotension were reported more often with Retatrutide than with placebo in TRIUMPH-2 ^[7]

Implications for Research Peptide Procurement

The clinical success of Retatrutide has driven substantial demand for the research-grade compound. Laboratories conducting in vitro receptor binding studies, pharmacokinetic modelling, and comparative analyses against Semaglutide and Tirzepatide require verified, high-purity material. Impurities can matter even at low levels: in one documented case, a contaminating peptide present at about 1% by weight produced false-positive results in T-cell assays ^[9].

When sourcing Retatrutide for research, critical quality parameters include:

• HPLC purity verification (not less than 99%)
• Mass spectrometry confirmation of molecular identity
• Endotoxin testing (below 0.5 EU/mg for cell culture applications)
• Documented supplier verification

Regulatory Timeline

Eli Lilly has said it plans to submit a Biologics License Application for Retatrutide to the US FDA in the first quarter of 2027, once its manufacturing data package is complete (Lilly, July 2026). Researchers studying the compound now are positioning their work ahead of the expected surge in clinical and academic interest following regulatory decisions.

References

1. [1] Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial." N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972. PubMed 37366315
2. [2] Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021;384(11):989-1002. PubMed 33567185
3. [3] Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022;387(3):205-216. PubMed 35658024
4. [4] Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metab. 2022;34(9):1234-1247. PubMed 35985340
5. [5] Sanyal AJ, et al. "Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial." Nat Med. 2024;30(7):2037-2048. PubMed 38858523
6. [6] Jastreboff AM, et al. "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." N Engl J Med. 2026 (online ahead of print). PubMed 42814954
7. [7] Bellido V, et al. "Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial." Lancet. 2026 (online ahead of print). PubMed 42810372
8. [8] Bajaj HS, et al. "Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial." Lancet. 2026;407(10546):2402-2413. PubMed 42250575
9. [9] Currier JR, et al. "Peptide impurities in commercial synthetic peptides and their implications for vaccine trial assessment." Clin Vaccine Immunol. 2008;15(2):267-276. PubMed 18077621